Abstract:Cancer immunotherapy harnesses the immune system to combat tumors and has emerged as a major cancer treatment modality. The PD-1/PD-L1 immune checkpoint modulates interactions between tumor cells and T cells and has been extensively targeted in cancer immunotherapy. However, the monoclonal antibodies known to target this immune checkpoint have considerable side effects, and novel PD-1/PD-L1 inhibitors are therefore required. Herein, a peptide inhibitor to disrupt PD-1/PD-L1 interactions was designed through structure-driven phage display engineering coupled to computational modification and optimization. BetaPb, a novel peptide library constructed by using the known structure of PD-1/PD-L, was used to develop inhibitors against the immune checkpoint, and specific peptides with high affinity toward PD-1 were screened through enzyme-linked immunosorbent assays, homogeneous time-resolved fluorescence, and biolayer interferometry. A potential inhibitor, B8, was preliminarily screened through biopanning. The binding affinity of B8 toward PD-1 was confirmed through computation-aided optimization. Assessment of B8 variants (B8.1, B8.2, B8.3, B8.4, and B8.5) demonstrated their attenuation of PD-1/PD-L1 interactions. B8.4 exhibited the strongest attenuation efficiency at a half-maximal effective concentration of 0.1 μM and the strongest binding affinity to PD-1 (equilibrium dissociation constant = 0.1 μM). B8.4 outperformed the known PD-1/PD-L1 interaction inhibitor PL120131 in disrupting PD-1/PD-L1 interactions, revealing that B8.4 has remarkable potential for modification to yield an antitumor agent. This study provides valuable information for the future development of peptide-based drugs, therapeutics, and immunotherapies for cancer.

Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis

Design and Evaluation of Α-Helix-based Peptide Inhibitors for Blocking PD-1/PD-L1 Interaction.

Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?

Pd-1-Targeted Discovery Of Peptide Inhibitors By Virtual Screening, Molecular Dynamics Simulation, And Surface Plasmon Resonance

Develop a PD-1-blockade Peptide to Reinvigorate T-cell Activity and Inhibit Tumor Progress.

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice

Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.

Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy.

A Peptidic Inhibitor for PD-1 Palmitoylation Targets Its Expression and Functions.

Blocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer Immunotherapy

Discovery of Peptide Inhibitors Targeting Human Programmed Death 1 (PD-1) Receptor.

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction

Targeting Β-Catenin and PD-L1 Simultaneously by a Racemic Supramolecular Peptide for the Potent Immunotherapy of Hepatocellular Carcinoma.

Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Discovery of Phenyl-Linked Symmetric Small Molecules As Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction